APN-401 is under clinical development by InvIOs and currently in Phase I for Head And Neck Squamous Cell Carcinoma (HNSC). According to GlobalData, Phase I drugs for Head And Neck Squamous Cell Carcinoma (HNSC) have a 79% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how APN-401’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

APN-401 overview

APN-401 is under development for the treatment of various solid tumors, head and neck cancer squamous cell carcinoma. It is an autologous cell therapy. The drug candidate is administered through intravenous route and acts by targeting the E3 ubiquitin ligase Cbl-b.

It was under development for the treatment of melanoma, renal carcinoma (kidney), metastatic pancreatic cancer, metastatic colorectal cancer.

InvIOs overview

InvIOs, a subsidiary of APEIRON Biologics AG, is a biotech company that focused on the discovery and development of cancer immunotherapies. InvIOs is headquartered in Vienna, Austria.

For a complete picture of APN-401’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.